IDEAYA Biosciences/IDYA

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About IDEAYA Biosciences

IDEAYA Biosciences, Inc. is a precision medicine oncology company. The Company is engaged in the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its lead product candidates are darovasertib (IDE196), IDE397, IDE161 and GSK101 (Pol Theta Helicase). IDE196, a small molecule protein kinase C (PKC), inhibitor, in combination with crizotinib, an investigational cMET inhibitor. IDE397, is its small molecule methionine adenosyltransferase 2a (MAT2A), inhibitor. IDE161, is its small molecule poly (ADP-ribose) glycohydrolase (PARG), inhibitor. IDE196 is its clinical-stage PKC inhibitor that the Company is evaluating as a synthetic lethal combination therapy. IDE397, a MAT2A inhibitor for patients with solid tumors having MTAP deletions. IDE161 is its clinical-stage, potent and selective small molecule inhibitor of PARG for patients having tumors with defined biomarkers based on genetic mutations and/or molecular signatures.

Ticker

IDYA

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Yujiro Hata

Employees

124

Headquarters

South san francisco, United States

IDYA Metrics

BasicAdvanced
$2.8B
Market cap
-
P/E ratio
-$2.00
EPS
0.78
Beta
-
Dividend rate
$2.8B
0.78358
$47.74
$20.90
732K
28.42
-19.44%
-20.31%
-20.27%
178.428
2.922
2.958
-67.33%
-31.43%
6.17%

What the Analysts think about IDYA

Analyst Ratings

Majority rating from 11 analysts.
Buy

IDYA Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0.00% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
-100.00%
Net income
-$40M
16.52%
Profit margin
0.00%
-100.00%

IDYA Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 2.99%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.50
-$0.46
-$0.52
-$0.53
-
Expected
-$0.56
-$0.49
-$0.47
-$0.51
-$0.54
Surprise
-10.16%
-7.00%
11.23%
2.99%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
Market open

Upcoming events

No upcoming events

FAQs

What’s the current market cap for IDEAYA Biosciences stock?

IDEAYA Biosciences (IDYA) has a market cap of $2.8B as of June 17, 2024.

What is the P/E ratio for IDEAYA Biosciences stock?

The price to earnings (P/E) ratio for IDEAYA Biosciences (IDYA) stock is 0 as of June 17, 2024.

Does IDEAYA Biosciences stock pay dividends?

No, IDEAYA Biosciences (IDYA) stock does not pay dividends to its shareholders as of June 17, 2024.

When is the next IDEAYA Biosciences dividend payment date?

IDEAYA Biosciences (IDYA) stock does not pay dividends to its shareholders.

What is the beta indicator for IDEAYA Biosciences?

IDEAYA Biosciences (IDYA) has a beta rating of 0.78. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

What is the IDEAYA Biosciences stock price target?

The target price for IDEAYA Biosciences (IDYA) stock is $53.4, which is NaN% below the current price of $. This is an average based on projections from 10 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell IDEAYA Biosciences stock

Buy or sell IDEAYA Biosciences stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing